ABEO

Abeona Therapeutics Inc.

A developer of gene and cell therapies for rare, life-threatening diseases. Its first approved treatment, ZEVASKYN, uses a patient's own skin cells to heal the painful, hard-to-close wounds of recessive dystrophic epidermolysis bullosa, a disorder that gives children skin so fragile they're called "butterfly children." The company, formerly named PlasmaTech Biopharmaceuticals, took the name Abeona from the Roman goddess who protects children, reflecting its focus on young patients with serious genetic conditions.

CUSIP: 00289Y107HealthcareUS1 holder

Ownership Activity Financials Filings

ABEO

ABEO

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Other Events

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year